CB2 receptors on immune cells could be a drug target for HIV-related brain inflammation
A review proposes CB2 cannabinoid receptors as therapeutic targets for HIV-associated neurocognitive disorder, noting that HIV patients using medical marijuana have lower levels of inflammatory monocytes.
Quick Facts
What This Study Found
HIV patients using medical marijuana had lower levels of circulating CD16+ (activated) monocytes compared to non-cannabis users. CD16+ monocytes carry HIV across the blood-brain barrier and drive neuroinflammation in HAND. CB2 receptor activation suppresses monocyte activation, chemotaxis, and inflammatory mediator release. The review proposes CB2 as a therapeutic target because it mediates anti-inflammatory effects without the psychotropic properties associated with CB1.
Key Numbers
~38 million people living with HIV; ~50% develop HAND; HIV patients on medical marijuana showed lower CD16+ monocyte levels than non-users.
How They Did This
Narrative review synthesizing evidence on HAND pathophysiology, endocannabinoid immunology, and clinical observations in HIV patients using medical cannabis, proposing CB2 as a therapeutic target.
Why This Research Matters
About 50% of HIV patients develop neurocognitive dysfunction despite antiretroviral therapy. Current treatments do not adequately address the neuroinflammation driving HAND. CB2-targeted therapy could reduce brain inflammation without psychotropic effects.
The Bigger Picture
If CB2 agonists can reduce the activated monocytes that carry HIV into the brain, this approach could complement antiretroviral therapy by addressing the inflammatory component that current drugs miss.
What This Study Doesn't Tell Us
Review based on observational clinical data and preclinical mechanistic studies; no RCTs of CB2 agonists for HAND; lower CD16+ monocytes in cannabis users could reflect confounding; CB2-selective drugs are not yet clinically available.
Questions This Raises
- ?Would a CB2-selective agonist reduce HAND progression in a clinical trial?
- ?Does whole cannabis use improve neurocognitive outcomes in HIV patients?
Trust & Context
- Key Stat:
- 50% of HIV patients develop brain inflammation; cannabis users showed fewer inflammatory monocytes
- Evidence Grade:
- Moderate: well-reasoned mechanistic review with clinical observations, but no direct CB2-targeted clinical trials.
- Study Age:
- Published 2020.
- Original Title:
- Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.
- Published In:
- Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 15(4), 780-793 (2020)
- Authors:
- Rizzo, Michael D(3), Henriquez, Joseph E(3), Blevins, Lance K(2), Bach, Anthony, Crawford, Robert B, Kaminski, Norbert E
- Database ID:
- RTHC-02802
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis help with HIV-related brain problems?
HIV patients using medical marijuana showed lower levels of the inflammatory immune cells (CD16+ monocytes) that carry HIV into the brain. The authors propose that CB2 receptor-targeted drugs could reduce this neuroinflammation without causing a high.
What is HAND?
HIV-Associated Neurocognitive Disorder affects about half of HIV patients. It results from chronic brain inflammation driven by activated monocytes crossing the blood-brain barrier and recruiting immune cells that damage neurons.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02802APA
Rizzo, Michael D; Henriquez, Joseph E; Blevins, Lance K; Bach, Anthony; Crawford, Robert B; Kaminski, Norbert E. (2020). Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 15(4), 780-793. https://doi.org/10.1007/s11481-020-09918-7
MLA
Rizzo, Michael D, et al. "Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.." Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2020. https://doi.org/10.1007/s11481-020-09918-7
RethinkTHC
RethinkTHC Research Database. "Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to..." RTHC-02802. Retrieved from https://rethinkthc.com/research/rizzo-2020-targeting-cannabinoid-receptor-2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.